Experts to discuss how the revolutionary technology is used today and can reshape the future

Experts of 3D printing will discuss how the innovation could change drug discovery and health delivery, at the DIA 2014 50th Annual Meeting in San Diego. “Health Care’s Revolutionary Printing Press? 3D Printing – Blue Sky and Regulatory Path,” to be held on June 17 at 10:30 a.m. at the San Diego Convention Center, will identify the uses of 3D printing, the ways the technology can change medical product development and challenges in regulation.

“As 3D printing emerges on the health care landscape, it is not fully known how the bold technology may transform the industry as we know it today,” said Barbara L. Kunz, DIA global chief executive. “The DIA Annual Meeting will bring together subject matter experts behind 3D printing to explain how it will impact all arenas of drug development.”

3D printers use digital, three-dimensional design data to create medical products such as customized joint replacements. By building up a product layer by layer based on a digital model, a solid object of virtually any shape can be produced. The technology offers shorter production times and can save money by using fewer raw materials than do more traditional manufacturing methods. 3D printing capabilities are increasing—such as producing printed drugs, new tissue and bones—but regulatory guidelines do not yet exist.

Chaired by Nancy Bradish Myers, president and founder of Catalyst Healthcare Consulting, Inc., the session will feature a presentation about scientific policy on 3D printers by a representative of the Food and Drug Administration’s Office of Device Evaluation, and an industry perspective from Eric David, co-founder and chief strategy officer of Organovo.    

 

Contact: Tiffany Cohen
+1.202.499.4411
tcohen@reingold.com

 

###